Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

I enjoy my exchanges with you as well. They are always informative. Yes, the comparison between Onko-Sure and J & J is like that between apples and oranges. Was it RPC actually comparing themselves to J & J's proposed test or was it more of a defensive press release? From what I remember reading it seemed to be the latter. I think that the J & J proposed test story was released and people were raising questions of the usefulness/ marketability of Onko-Sure in an environment containing the J & J test. If you have any links, I would like to take a look.

Yes, I could definitely see it as a therapeutic monitoring test. However, again you run into the problem of it possibly only being effective at a later stage of cancer. Regardless, the late stage cancer market is huge. If it can be as effective as J & J hopes then is certainly worth the 51 million dollar development price tag.

Thanks in advance for the information.